Please assess the completion status of the following clinical trial:

Trial Title: Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female infants and toddlers aged 3 - 48 months (inclusive) at enrolment (Day 0).~2. Caretaker(s) answering yes to the question Do you feel that your child has a cold? at enrolment (Day 0).~3. Subjects with symptoms started within 48 hours prior to enrolment (Day 0).~4. Subjects with nasal congestion (blocked / stuffy nose) rated as at least grade 2 (moderately bothersome) on a 0 to 2-point scale, based on morning evaluation (within an hour of subject awakening).~5. Subjects showing at least grade 2 on a 0 to 2-point scale for at least one of the following additional signs of cold symptoms: runny nose, nasal crust (dry mucus), thick mucus, sneezing and cough.~6. Legal caretaker(s) signed written informed consent for their young ones to participate in the study.~7. Legal caretaker(s) willing to comply with all study procedures.~8. Ability of the caretaker(s) (in the Investigator's opinion) to comprehend the full nature, procedures, and purpose of the study.~Exclusion Criteria:~1. Subjects presenting a body temperature greater than 38°C measured with a non-contact infrared thermometer at enrolment (Day 0).~2. Subjects presenting any secondary infection (such as bronchitis, otitis, tracheitis, pneumonia, and so on) at enrolment (Day 0).~3. Subjects with positive results on a streptococcal antigen screening test (rapid antigen detection test or RADT) at enrolment (Day 0).~4. Subjects with history of allergic rhinitis.~5. Subjects presenting any congenital or chronic disease that in the opinion of the Investigator would adversely affect the results of the study (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, and so on).~6. Subjects presenting any kind of immunodeficiency.~7. Subjects presenting any hypersensitivity or allergy or intolerance to any component of the study products.~8. Subjects with a positive medical history to any significant illness within the 2 weeks prior to the enrolment (Day 0).~9. Subjects presenting any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.~10. Subjects currently participating or having participated in another clinical trial during the last 30 days prior to enrolment (Day 0).~11. Subjects using saline nose drops or nasal sprays or pumps other than the study products, antibiotics, antivirals, intranasal medicines, decongestants, antihistamines, echinacea, combination cold formulas, supplements containing ≥ 10 mg zinc that would influence symptoms scores at enrolment (Day 0) within 12 hours prior the day of screening.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): IP1 - Stérimar BLOCKED NOSE Baby nasal spray + standard of care
- Group B (Type: EXPERIMENTAL): IP2 - Stérimar Stop \& Protect Cold Baby + standard of care
- Group C (Type: OTHER): Standard of Care alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues